Here are the 424B prospectus supplements from TCGX Acquisition Corp. (TCGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TCGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCGX filings page.
TCGX Acquisition Corp. (TCGX), a Cayman Islands blank check company focused on healthcare (especially life sciences and medtech, including potential targets in China), is conducting an IPO of 7,500,000 Class A ordinary shares at $10.00 per share, for $75,000,000 in gross proceeds. The underwriters have a 45‑day option to buy up to 1,125,000 additional shares.
$75,000,000 (or $86,250,000 with the over‑allotment) plus private placement proceeds will be placed in a U.S. trust account at $10.00 per share. Public holders can redeem in connection with the initial business combination or certain extensions, generally at trust value per share, but any holder (together with affiliates and group members) is limited to redeeming more than 15% of IPO shares without consent. If no business combination is completed within 24 months (subject to shareholder‑approved extensions), TCGX will liquidate and redeem public shares.
The sponsor and underwriters will buy 500,000 private placement shares at $10.00 (up to 522,500 with over‑allotment), and the sponsor and insiders already hold 2,156,250 Class B founder shares bought for $25,000, designed to represent 20% of post‑IPO shares (excluding private placement). Founder shares convert into Class A on at least a one‑for‑one basis with anti‑dilution protection, creating potential material dilution for public investors. A forward purchase agreement with Fund III commits a minimum of 2,000,000 additional Class A shares at $10.00 at business‑combination closing, subject to Fund III investment committee approval.